Replimune Group (NASDAQ:REPL) Trading Down 4.7% – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL)’s share price was down 4.7% during trading on Tuesday . The company traded as low as $11.83 and last traded at $11.89. Approximately 266,350 shares changed hands during trading, a decline of 75% from the average daily volume of 1,044,736 shares. The stock had previously closed at $12.48.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Roth Mkm began coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, BMO Capital Markets increased their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus price target of $17.29.

Replimune Group Stock Performance

The business has a 50 day moving average price of $12.22 and a 200 day moving average price of $10.58. The stock has a market cap of $801.85 million, a P/E ratio of -3.95 and a beta of 1.26. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group, Inc. will post -2.91 EPS for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently modified their holdings of REPL. Nisa Investment Advisors LLC lifted its stake in shares of Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new position in shares of Replimune Group during the 2nd quarter worth approximately $57,000. Arizona State Retirement System purchased a new stake in Replimune Group during the second quarter valued at approximately $108,000. Quest Partners LLC boosted its stake in Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Replimune Group in the third quarter worth $133,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.